## 3 Results  
### Each Index Comparison between Two Group Conditions, Ubiquinol and Placebo  
The measured molecular concentrations in blood, psychological questionnaire scores, and IR signals detected on the body surface in Group A (Term 1: placebo and Term 2: ubiquinol), Group B (Term 1: ubiquinol and Term 2: placebo), and total (the sum of Group A and Group B) are shown in Figure 3. It was confirmed that the participants were compliant with the treatment (ubiquinol or placebo) in each condition, which was confirmed by the difference (\(p<0.05\)) in sUbiquinol (ubiquinol in serum; sQH) between study conditions. No other parameter was significantly different when comparing the two conditions ubiquinol (QH: blue) and placebo (P: orange). \begin{table}
\begin{tabular}{c c c c c} \hline
**Marker** & **Molecule in Blood Serum** & \multicolumn{3}{c}{**[PERSON]’s Product-Moment Correlation with sUbiquinol**} \\ \cline{2-5}  & & **R** & **t** & **_p_** \\ \hline sUbiquinol & Ubiquinol: reduced coenzyme Q10 & **-** & - & - \\ \hline sUbiquinone & Ubiquinone: oxidized coenzyme Q10 & **0.798** & **6.492** & **0.000 *** \\ \hline TSH & Thyrotropin & \(-0.180\) & \(0.898\) & \(0.378\) \\ \hline IL-4 & Interleukin 4 & \(-\)**0.347** & \(-\)**1.811** & **0.0827 (*)** \\ \hline ADH & Antidiuretic hormone (vasopressin) & \(-0.015\) & \(0.073\) & \(0.942\) \\
**Marker** & **Infrared intensity** & & & \\ IR\_sd & Body surface temperature: standard deviation & \(0.256\) & \(1.295\) & \(0.208\) \\ \hline IR\_ave & Body surface temperature: average & \(0.329\) & \(1.7056\) & \(0.101\) \\
**Marker** & **Psychological questionnaire** & **0.502** & **2.844** & **0.00897 *** \\ \hline STAI-positive & State–Trait Anxiety Inventory (positive mood) & \(-0.226\) & \(1.137\) & \(0.267\) \\ \hline BDI-II & Beck Depression Inventory-II & \(-0.277\) & \(1.410\) & \(0.171\) \\ \hline \end{tabular}
\end{table} 
Table 1: The correlation analyses between sUbiquinol and markers of biomolecules, body surface temperatures, and psychological scores. R is [PERSON]’s product-moment correlation coefficient. The t-value is the t-distribution size of the difference relative to the variation in sample data. \(p\) value is the probability ((*): \(p<0.1\), **: \(p<0.01\), and ***: \(p<0.001\)). BOIQUET Reveals a Moderate Association of Uliquinol Intake with \"STAI-Positive\" and a \"BDI-II\" Reveals a Weak Association with \"II-4\"  
The multivariate analysis of the collected indices revealed that the coordinates of the first and second components for Group A (shifting from placebo to ubiquinol) were not significant, as shown in Figure 4b (Wilks' lambda; \(p\) = 0.2407), nor were the first and second components for Group B (shifting from ubiquinol to placebo), as shown in Figure 4c. However, Figure 4a indicates that when considering the total, the data were finally significant (* \(p\) = 0.04926). These coordinates and the distribution of Groups A and B are summarized as each total variance ellipse for either Group A or B consistently. It is worth noting that the eigenvector of \"STAI-positive\" is pointed in a similar direction to \"sUbiquinol\", and the shorter eigenvectors of \"BDI-II\" and \"II-4\" are pointed in opposite directions. \"IR_sd\" was a shorter eigenvector positioned near \"STAI-positive\" and \"sUbiquinol\", in an opposite direction to \"BDI-II\". Figure 3: Single-pair comparisons in all the collected data. In Group A, Term 1 is placebo (T1(P)), and Term 2 is ubiquinol (T2(QH)). Group B is reversed; Term 1 is ubiquinol (T1(QH)), and Term 2 is placebo (T2(P)). The final panel in the grouping is the summarized comparison between P and QH intake conditions combining Groups A and B. The statistical results by one-way ANOVA are marked with asterisks ((*): \(p\) < 0.1, *: \(p\) < 0.05, **: \(p\) < 0.01, and ***: \(p\) < 0.001) and thick values (\(p\) < 0.25).